Lv71
5000 积分 2022-03-11 加入
No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry
4小时前
已完结
Real-World Data Analysis on Early Mortality in Chinese Multiple Myeloma Patients: Analysis of 1093 Patients During a 15-Year Period
5天前
已关闭
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma
9天前
已完结
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma
11天前
已完结
Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
12天前
已完结
Measurable residual disease assessment in multiple myeloma
12天前
已完结
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
13天前
已完结
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
13天前
已完结
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference
13天前
已完结
Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition
1个月前
已完结
皖公网安备34019202002308
